Request Trial
HenadziPechan / Shutterstock.com
25 August 2026NewsRegulation & IndustryMarisa Woutersen

The buyers' wishlist: What makes a life sciences deal stack up?

While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal. 

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Regulation & Industry
Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
14 September 2026   Pitching for business has always been a partner’s game. One in-house team decided junior lawyers needed a seat at the table, building a programme to close an “industry-wide gap” in vital experience. Marisa Woutersen spoke with organisers Regeneron and associates from A&O Shearman, Hoyng Rokh Monegier, and Bristows, who stepped up to ‘sell’ their firms.
Regulation & Industry
Built to be bought? What makes companies acquisition-ready
11 September 2026   For biotech companies, promising science is no longer enough to attract a pharma buyer. Lawyers from Morrison Foerster, Polsinelli, Morgan Lewis and Dechert explain what makes an acquisition target truly deal-ready. Marisa Woutersen explores what companies should get right before a potential acquirer comes knocking.
Regulation & Industry
Patent lawyers and judges discuss lofty UPC issues in grand London venue
10 September 2026   UPC judges and practitioners from firms including Freshfields, Kather Augenstein, EIP, Simmons & Simmons and Brinkhof converged at CIPA’s annual conference to offer candid views on the court’s biggest pressure points, from overloaded German divisions to harmonisation and cross-court influence.


Editor's picks

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
Regulation & Industry
Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
14 September 2026

Editor's picks

Regulation & Industry
Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
14 September 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026

More features

Australian biotech sues Grail over multi-cancer blood test
K&L Gates hires six-partner team of IP and corporate lawyers from Pillsbury
Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
Built to be bought? What makes companies acquisition-ready
Patent lawyers and judges discuss lofty UPC issues in grand London venue
J&J names two-decade veteran as chief IP counsel
J&J unit win shuts door on Sandoz generic launch
Abbott clinches 18-country PI in glucose monitoring feud